DK404187D0 - Fremgangsmaade til fremstilling af thiazolderivater - Google Patents

Fremgangsmaade til fremstilling af thiazolderivater

Info

Publication number
DK404187D0
DK404187D0 DK404187A DK404187A DK404187D0 DK 404187 D0 DK404187 D0 DK 404187D0 DK 404187 A DK404187 A DK 404187A DK 404187 A DK404187 A DK 404187A DK 404187 D0 DK404187 D0 DK 404187D0
Authority
DK
Denmark
Prior art keywords
thiazold
derivatives
procedure
preparation
thiazold derivatives
Prior art date
Application number
DK404187A
Other languages
English (en)
Other versions
DK404187A (da
DK175022B1 (da
Inventor
Peter Bod
Kalman Harsanyi
Bela Hegedues
Erik Bogsch
Eva Fekecs
Imre Peter
Zsuzsanna Aracs
Sandor Miszori
Maria Stiller
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10963778&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK404187(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of DK404187D0 publication Critical patent/DK404187D0/da
Publication of DK404187A publication Critical patent/DK404187A/da
Application granted granted Critical
Publication of DK175022B1 publication Critical patent/DK175022B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK198704041A 1986-08-05 1987-08-03 Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B DK175022B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU863370A HU196775B (en) 1986-08-05 1986-08-05 Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
HU337086 1986-08-05

Publications (3)

Publication Number Publication Date
DK404187D0 true DK404187D0 (da) 1987-08-03
DK404187A DK404187A (da) 1988-02-06
DK175022B1 DK175022B1 (da) 2004-04-26

Family

ID=10963778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198704041A DK175022B1 (da) 1986-08-05 1987-08-03 Fremgangsmåde til fremstilling af en morfologisk homogen polymorf af Famotidin form B

Country Status (18)

Country Link
US (3) US4894459A (da)
EP (1) EP0256747B2 (da)
JP (2) JP2644234B2 (da)
KR (1) KR940003954B1 (da)
CN (1) CN1024275C (da)
AR (1) AR243175A1 (da)
AT (1) ATE82274T1 (da)
AU (1) AU604040B2 (da)
BG (1) BG60496B2 (da)
CA (1) CA1265809A (da)
CS (1) CS268188B2 (da)
DE (2) DE256747T1 (da)
DK (1) DK175022B1 (da)
FI (1) FI89917C (da)
GR (1) GR871216B (da)
HU (1) HU196775B (da)
PH (1) PH24069A (da)
PT (1) PT85473B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86330A0 (en) * 1987-06-22 1988-11-15 Marga Investigacion Famotidine polymorphic forms and their preparation
AU691195B2 (en) * 1993-07-09 1998-05-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CA2426122A1 (en) * 2002-05-02 2003-11-02 M/S Tonira Pharma Limited A process for the preparation of a combination of famotidine polymorphis a and b
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
CA2505335C (en) 2002-12-11 2013-09-10 Daniel Aaron Moros Method of treating movement disorders using barbituric acid derivatives
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
EP1781624A4 (en) * 2004-07-02 2010-06-23 Taro Pharma Ind PROCESS FOR THE PREPARATION OF 1-METHOXYMETHYL-5,5-DIPHENYLBARBITURIC ACID
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
CN101257800B (zh) * 2005-07-18 2012-07-18 好利用医疗公司 包含法莫替丁和布洛芬的药物
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
CA2657928C (en) 2006-07-18 2014-12-02 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543238A (en) * 1976-09-21 1979-03-28 Smith Kline French Lab Polymorph of cimetidine
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
JPS5655383A (en) * 1979-10-12 1981-05-15 Yamanouchi Pharmaceut Co Ltd Amizine derivative and its preparation
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
US4496737A (en) * 1982-09-27 1985-01-29 Merck & Co., Inc. Process for preparing sulfamylamidine antisecretory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86330A0 (en) * 1987-06-22 1988-11-15 Marga Investigacion Famotidine polymorphic forms and their preparation

Also Published As

Publication number Publication date
CN87105373A (zh) 1988-06-08
BG60496B2 (bg) 1995-05-31
US5128477A (en) 1992-07-07
EP0256747B2 (en) 2001-11-28
AU604040B2 (en) 1990-12-06
US4894459A (en) 1990-01-16
DE3782576T2 (de) 1993-03-25
AU7654287A (en) 1988-02-11
JPH07316141A (ja) 1995-12-05
JP2644234B2 (ja) 1997-08-25
FI873346A (fi) 1988-02-06
KR940003954B1 (ko) 1994-05-09
JP2708715B2 (ja) 1998-02-04
PH24069A (en) 1990-03-05
EP0256747A1 (en) 1988-02-24
CA1265809A (en) 1990-02-13
CN1024275C (zh) 1994-04-20
DK404187A (da) 1988-02-06
PT85473B (pt) 1990-06-29
US5120850A (en) 1992-06-09
DE3782576T3 (de) 2002-08-08
AR243175A1 (es) 1993-07-30
EP0256747B1 (en) 1992-11-11
CS579987A2 (en) 1989-04-14
FI873346A0 (fi) 1987-08-03
FI89917B (fi) 1993-08-31
JPS6399065A (ja) 1988-04-30
FI89917C (fi) 1993-12-10
HU196775B (en) 1989-01-30
HUT45240A (en) 1988-06-28
PT85473A (en) 1987-09-01
GR871216B (en) 1987-11-19
DE256747T1 (de) 1988-11-24
CS268188B2 (en) 1990-03-14
KR880002847A (ko) 1988-05-11
ATE82274T1 (de) 1992-11-15
DE3782576D1 (de) 1992-12-17
DK175022B1 (da) 2004-04-26

Similar Documents

Publication Publication Date Title
DK404187A (da) Fremgangsmaade til fremstilling af thiazolderivater
DK86193D0 (da) Fremgangsmaade til fremstilling af trifluorbenzoesyrederivater
DK250689D0 (da) Fremgangsmaade til fremstilling af napthalenderivater
DK165984C (da) Fremgangsmaade til fremstilling af sphingosinderivater
DK375987A (da) Fremgangsmaade til fremstilling af cycloalkyl-sub-stituerede 4-pyridyl derivater
DK30489A (da) Fremgangsmaade til fremstilling af pyranderivater
DK537687A (da) Fremgangsmaade til fremstilling af n-substituerede piperazinoner
DK516286A (da) Fremgangsmaade til fremstilling af oxazolderivater
DK314988A (da) Fremgangsmaade til fremstilling af 6-deoxyguaninderivater
DK28788D0 (da) Fremgangsmaade til fremstilling af alkansulfonamider
DK601489A (da) Fremgangsmaade til fremstilling af alkansulfonamider
DK143889A (da) Fremgangsmaade til fremstilling af naphthalenderivater
DK158224C (da) Fremgangsmaade til fremstilling af indolderivater
DK533287D0 (da) Fremgangsmaade til fremstilling af azetidinoner
DK293589D0 (da) Fremgangsmaade til fremstiling af lactolderivater
DK558487A (da) Fremgangsmaade til fremstilling af moertel
DK184687D0 (da) Fremgangsmaade til fremstilling af diacetonesorbose
DK184789A (da) Fremgangsmaade til fremstilling af naphthalenderivater
DK599689D0 (da) Fremgangsmaade til fremstilling af naphthalenderivater
DK256786A (da) Fremgangsmaade til fremstilling af triazolderivater
DK291785A (da) Fremgangsmaade til fremstilling af iminderivater
DK26888A (da) Fremgangmsaade til fremstilling af diaminoalkanderivater
DK162789D0 (da) Fremgangsmaade til fremstilling af alkalimetalphenylpyruvat
DK234687A (da) Fremgangsmaade til fremstilling af ribitylxylidin
DK64085A (da) Fremgangsmaade til fremstilling af imidazolderivater

Legal Events

Date Code Title Description
PUP Patent expired